The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis
作者： Wei Wei , Xin Chen , Ximeng Ma , Dawei Wang , Zongze Guo
DOI: 10.1007/S11060-015-1920-0
关键词:
摘要: The goal of this meta-analysis was to identify the temozolomide (TMZ) regimen with optimal efficacy and tolerance for treatment recurrent high-grade glioma (HGG). PubMed EMBASE databases were searched from earliest records February 2015, which identified 33 studies 1760 participants that met inclusion criteria. standard schedule three most common dose-dense regimens TMZ therapy HGG included in meta-analysis. 7 days on/7 off grade IV gliomas significantly superior respect progression-free survival at 6 months (34.8 %; 95 % confidence interval (CI) 27.0-43.4 %) 12 (15.5 CI 10.7-21.8 %). For III gliomas, conveyed a greater overall (OS) rate (79.0 56.2-91.7 %), as compared schedule. Also, 21 had longer OS rates (73.6 63.4-81.8 (40.6 32.6-48.6 than gliomas. In addition, showed higher clinical benefit regimens. However, 3-4 toxicity lymphopenia 76.5 (95 45.5-92.7 highest among four Recurrent patients receiving personalized should be closely followed up, especially those concurrent hematological diseases.
springer.com
sci-hub.se 参考文章(62)
Marco Hassler, Michael Micksche, Günther Stockhammer, Josef Pichler, Franz Payer, Brigitte Abuja, Robert Deinsberger, Christine Marosi, Temozolomide for recurrent or progressive high-grade malignant glioma: results of an Austrian multicenter observational study. Wiener Klinische Wochenschrift. ,vol. 118, pp. 230- 238 ,(2006) , 10.1007/S00508-006-0576-3
James R. Perry, Philippe Rizek, Rosemary Cashman, Meredith Morrison, Tara Morrison, Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule Cancer. ,vol. 113, pp. 2152- 2157 ,(2008) , 10.1002/CNCR.23813
Michael J. Tisdale, Antitumour imidazotetrazines—XV: Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones Biochemical Pharmacology. ,vol. 36, pp. 457- 462 ,(1987) , 10.1016/0006-2952(87)90351-0
Douglas G. Altman, Michael J. Bradburn, Roger M. Harbord, Jonathan A. C. Sterne, Ross J. Harris, Jonathan J. Deeks, metan: fixed- and random-effects meta-analysis Stata Journal. ,vol. 8, pp. 3- 28 ,(2008) , 10.1177/1536867X0800800102
Oliver-Louis Chinot, Stephane Honore, Henry Dufour, Maryline Barrie, Dominique Figarella-Branger, Xavier Muracciole, Diane Braguer, Pierre-Marie Martin, François Grisoli, None, Safety and Efficacy of Temozolomide in Patients With Recurrent Anaplastic Oligodendrogliomas After Standard Radiotherapy and Chemotherapy Journal of Clinical Oncology. ,vol. 19, pp. 2449- 2455 ,(2001) , 10.1200/JCO.2001.19.9.2449
D R Macdonald, T L Cascino, S C Schold, J G Cairncross, Response criteria for phase II studies of supratentorial malignant glioma. Journal of Clinical Oncology. ,vol. 8, pp. 1277- 1280 ,(1990) , 10.1200/JCO.1990.8.7.1277
Susan M. Chang, Philip Theodosopoulos, Kathleen Lamborn, Mary Malec, Jane Rabbitt, Margaretta Page, Michael D. Prados, Temozolomide in the treatment of recurrent malignant glioma Cancer. ,vol. 100, pp. 605- 611 ,(2004) , 10.1002/CNCR.11949
Wolfgang Wick, Michael Weller, How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience. Journal of Clinical Oncology. ,vol. 23, pp. 4235- 4236 ,(2005) , 10.1200/JCO.2004.00.8417
W K A Yung, R E Albright, J Olson, R Fredericks, K Fink, M D Prados, M Brada, A Spence, R J Hohl, W Shapiro, M Glantz, H Greenberg, R G Selker, N A Vick, R Rampling, H Friedman, P Phillips, J Bruner, N Yue, D Osoba, S Zaknoen, V A Levin, A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse British Journal of Cancer. ,vol. 83, pp. 588- 593 ,(2000) , 10.1054/BJOC.2000.1316
Chao Chen, Tao Xu, Yicheng Lu, Juxiang Chen, Shenhong Wu, The efficacy of temozolomide for recurrent glioblastoma multiforme European Journal of Neurology. ,vol. 20, pp. 223- 230 ,(2013) , 10.1111/J.1468-1331.2012.03778.X